– USA, CA – STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer, and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigmatism, and presbyopia, today announced the appointment of Art Butcher and Wei Jiang to its Board of Directors, effective March 12, 2024, bringing the Board to eight members, of whom seven are independent directors.
“Art Butcher and Wei Jiang are seasoned executives with broad leadership experience built over decades at two of the most highly regarded global companies in the healthcare industry. Art and Wei also have particular expertise in APAC, the largest market in the world for refractive vision correction. We welcome them to the Board and look forward to leveraging their insights during this period of accelerating growth and innovation at STAAR,” said Aimee Weisner, Chair of the Nominating and Governance Committee.
About Arthur Butcher
Art Butcher brings extensive medical device marketing, strategy, and product development experience, including significant business experience in Asia. Art Butcher serves as EVP and Group President, MedSurg, and Asia Pacific for Boston Scientific, a position he has held since May 2022. Before his current role, Art Butcher was responsible for commercializing the company’s full portfolio of products across all divisions in the Asia Pacific region. Mr. Butcher joined Boston Scientific in 1997. He serves as a member of the Board of Directors of Acotec Scientific Holdings Limited, listed publicly on the Hong Kong Stock Exchange.
Art Butcher received a B.A. in International Relations from the University of Pennsylvania and an MBA from Columbia University.
About Wei Jiang
Wei Jiang brings more than 25 years of experience in the pharmaceutical and medical device industries, with a particular focus on China and the Asia/Pacific region. Mr. Jiang most recently served as EVP, of Bayer Pharmaceuticals Region China & APAC, and President, of Bayer Group Greater China Region, until his retirement in 2021. Before joining Bayer in 2012, he held various senior positions at AstraZeneca, culminating in his role as SVP, of China operations. Before that, Mr. Jiang served as Managing Director, of China operations at Guidant Corporation and in various roles at Eli Lilly & Company including Marketing Director, of China Operations. He currently serves as a member of the Board of Directors of Waters Corporation, listed publicly on the New York Stock Exchange.
Wei Jiang received a B.BA. in business administration from Campbell University in North Carolina and an M.A. in economics from Indiana State University.
STAAR also announced today that director K. Peony Yu., M.D., has indicated that she does not intend to stand for re-election to the Board upon the expiration of her current term in June 2024.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures, and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™ product line. More than 2,500,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA, and Nidau, Switzerland.
SOURCE: website at www.staar.com.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
